TICAGRELOR

Antiplatelet

Brand names: Ticagrelor, Brilinta

Oral

Mechanism of Action

12.1 Mechanism of Action Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.

Indications

1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death

myocardial infarction (MI)

and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS

myocardial infarction (MI)

and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS

Contraindications

• angioedema) to ticagrelor or any component of the product.

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Dyspnea was reported more frequently with ticagrelor than with control agents in clinical trials
1 Risk of Bleeding Drugs that inhibit platelet function including ticagrelor increase the risk of bleeding [see Warnings and Precautions ( 5
2 Discontinuation of Ticagrelor Tablets in Patients Treated for Coronary Artery Disease Discontinuation of ticagrelor tablets will increase the risk of myocardial infarction, stroke, and death in patients being treated for coronary artery disease
When possible, interrupt therapy with ticagrelor tablets for five days prior to surgery that has a major risk of bleeding

Known Side Effects

8 documented side effects by frequency

Shortness of Breath

>10%

Fatigue

1-10%

Chest Pain

1-10%

Dizziness

1-10%

Weakness

0.1-1%

General Unwellness

0.1-1%

Nausea

0.1-1%

Drug Not Working

0.1-1%

Community Discussions

No community discussions found for TICAGRELOR yet.

Compare With

8 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral